When.com Web Search

  1. Ad

    related to: eliquis 5 mg for stroke prevention

Search results

  1. Results From The WOW.Com Content Network
  2. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

    www.aol.com/news/2012-10-01-eliquis-apixaban...

    Patients were randomized to treatment with ELIQUIS 5 mg orally twice daily (or 2.5 mg twice daily in selected patients, representing 4.7 percent of all patients) or warfarin (target INR range 2.0 ...

  3. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.

  4. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

    www.aol.com/news/2013-01-02-us-fda-approves...

    U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

  5. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]

  6. New Eliquis® (apixaban) Post-hoc Subanalysis of the ... - AOL

    www.aol.com/2013/08/31/new-eliquis-apixaban-post...

    New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon Results ...

  7. Discovery and development of direct Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4] Betrixaban (Bevyxxa) was approved in the US in 2017.

  8. ELIQUIS® (apixaban) Approved In Japan For The Prevention Of ...

    www.aol.com/news/2012-12-26-eliquis-apixaban...

    The companies continue to progress the ELIQUIS application for stroke prevention in atrial fibrillation in other markets. On September 26, 2012, The U.S. Food and Drug Administration (FDA ...

  9. Vitamin K antagonist - Wikipedia

    en.wikipedia.org/wiki/Vitamin_K_antagonist

    We undertook a post-hoc analysis of data from the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation, n = 14,624) for stroke or non-CNS embolism within 30 days after temporary interruptions of 3 days or more, early permanent ...